

# LAURA VALLEJO TORRES, PhD

## PERSONAL DETAILS

---

Departamento de Métodos Cuantitativos en Economía y Gestión  
Universidad de Las Palmas de Gran Canaria  
Canary Islands, Spain

Email: laura.vallejo@ulpgc.es

## EDUCATION

---

2008-2011	Ph.D in Health Economics, University College London
2005-2006	MSc in Health Economics, University of York
2000-2004	BSc in Economics, Universidad de Las Palmas de Gran Canaria, Spain

## POSITIONS AND EMPLOYMENT

---

2017-present	Post-doctoral competitive researcher, Universidad de Las Palmas de Gran Canaria, Spain
2016-2017	Research Associate in Health Economics, Department of Applied Health Research, University College London, UK
2015-2017	Researcher, Fundación Canaria de Investigación Sanitaria (FUNCANIS), Spain
2013-2015	Researcher/lecturer, Department of Applied Economics and Quantitative Methods, University of la Laguna, Spain
2011-2013	Principal Research Associate in Health Economics, UCL Clinical Trials Unit, University College London, UK
2010-2013	Visiting Lecturer, Department of Economics, City University, London, UK
2008-2011	Ph.D Researcher, University College London, UK
2006-2008	Research Fellow, Health Economics Research Group, Brunel University, UK
2002-2004	Research Assistant, Department of Applied Economic Analysis, University of Las Palmas de Gran Canaria, Spain

## PUBLICATIONS IN PEER REVIEWED JOURNALS

---

1. **Vallejo-Torres L**, García-Lorenzo B, Rivero-Arias O, Pinto-Prades JL. 2019. The societal monetary value of a QALY associated with EQ-5D-3L health gains. *European Journal of Health Economics*. 2020; 21:363-379 (Impact factor: 2.367; Q1)

2. Zozaya N, **Vallejo-Torres L**. The Effect of the Economic Crisis on Adolescents' Perceived Health and Risk Behaviors: A Multilevel Analysis. 2020. *International Journal of Environmental Research and Public Health*, 2020; 17:2. (Impact factor: 2.849; Q1)
3. **Vallejo-Torres L**, Rivero-Santana A, Martin-Saborido C, Epstein D, Perestelo-Pérez L, Castellano-Fuentes CL, Escobar-Martínez A, Serrano-Aguilar P. Cost-effectiveness analysis of a surveillance program to prevent hip dislocation in children with cerebral palsy. *Gaceta Sanitaria*, 2020; 34(4): 377-384 (Impact factor: 1.564; Q3)
4. Suárez-Llanos JP, **Vallejo-Torres L**, García-Bello MA, Hernández-Carballo C, Calderón-Ledezma EM, Rosat-Rodrigo A, Delgado-Brito I, Pereyra-García-Castro F, Benitez-Brito N, Felipe-Pérez N, Ramallo-Fariña Y, Romero-Pérez JC. Cost-effectiveness of the hospital nutrition screening tool CIPA. *Archives of Medical Science*, 2020; 16(2):273-281. (Impact factor: 2.807; Q2)
5. Suárez-Llanos JP, Rosat-Rodrigo A, García-Niebla J, **Vallejo-Torres L**, Delgado-Brito I, García-Bello MA, Pereyra-García-Castro F, Barrera-Gómez MA. Comparison of Clinical Outcomes in Surgical Patients Subjected to CIPA Nutrition Screening and Treatment versus Standard Care. *Nutrients* 2019; 11(4). (Impact factor: 4.546; Q1)
6. Trujillo-Martín MM, Ramallo-Fariña Y, Del Pino-Sedeño T, Rúa-Figueroa Í, Trujillo-Martín E, **Vallejo-Torres L**, Imaz-Iglesia I, Sánchez-de-Madariaga R, de Pascual-Medina AM, Serrano-Aguilar P; SLE-CPG-Implementation Group. Effectiveness and cost-effectiveness of a multicomponent intervention to implement a clinical practice guideline for systemic lupus erythematosus: protocol for a cluster-randomized controlled trial. *BMC Health Serv Res* 2019; 19(1):783 (Impact factor: 1.987; Q3)
7. **Vallejo-Torres L**, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. *Health Econ.* 2018; 27(4):746-761 (Impact factor: 2.319; Q1)
8. **Vallejo-Torres L**, Morris S. 2017. Primary care supply and quality of care in England. *Eur J Health Econ.* 2018; 19(4):499-519 (Impact factor: 2.601; Q1)
9. García-Lorenzo B, Rivero-Santana A, **Vallejo-Torres L**, Castilla-Rodríguez I, García-Pérez S, García-Pérez L, Perestelo-Pérez L. Cost-effectiveness analysis of real-time continuous monitoring glucose compared to self-monitoring of blood glucose for diabetes mellitus in Spain. *J Eval Clin Pract.* 2018 Aug;24(4):772-781. (Impact factor: 1.483; Q3)
10. Gomila A, Carratalà J, Eliakim-Raz N, Shaw E, Wiegand I, **Vallejo-Torres L**, Gorostiza A, Vigo JM, Morris S, Stoddart M, Grier S, Vank C, Cuperus N, Van den Heuvel L, Vuong C, MacGowan A, Leibovici L, Addy I, Pujol M; COMBACTE MAGNET WP5 RESCUING Study Group and Study Sites. Risk factors and prognosis of complicated urinary tract infections caused by *Pseudomonas aeruginosa* in hospitalized patients: a retrospective multicenter cohort study. *Infect Drug Resist.* 2018; 18;11:2571-2581 (Impact factor: 3.443; Q2)
11. Gomila A, Carratalà J, Eliakim-Raz N, Shaw E, Wiegand I, **Vallejo-Torres L**, Gorostiza A, Vigo JM, Morris S, Stoddart M, Grier S, Vank C, Cuperus N, Van den Heuvel L, Vuong C, MacGowan A, Leibovici L, Addy I, Pujol M; COMBACTE MAGNET WP5 RESCUING Study Group and Study Sites. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections. *Antimicrob Resist Infect Control.* 2018 Sep 14;7:111. (Impact factor: 3.568; Q1)
12. **Vallejo-Torres L**, Melnychuk M, Vindrola-Padros C, Aitchison M, Clarke CS, Fulop NJ, Hines J, Levermore C, Maddineni SB, Perry C, Pritchard-Jones K, Ramsay AIG,

- Shackley DC, Morris S. Discrete choice experiment to analyse preferences for centralising specialist cancer surgery services. *British Journal of Surgery* 2018;105(5):587-596. (Impact factor: 5.899; Q1)
13. **Vallejo-Torres L**, Pujol M, Shaw E, Wiegand I, Vigo JM, Stoddart M, Grier S, Gibbs J, Vank C, Cuperus N, van den Heuvel L, Eliakim-Raz N, Carratala J, Vuong C, MacGowan A, Babich T, Leibovici L, Addy I, Morris S. The cost of hospitalised patients due to complicated urinary tract infections – A retrospective observational study in countries with high prevalence of multidrug resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study. *BMJ Open*; 2018; 12;8(4):e020251 (Impact factor: 2.369; Q1)
  14. **Vallejo-Torres L**, Morris S, González López-Valcárcel B. Obesity and perceived work discrimination in Spain. *Applied Economics*, 2018 [in press] (Impact factor: 0.648; Q3)
  15. Coloma M, Kang F, **Vallejo-Torres L**, Díaz P, Méndez Y, Álvarez de la Rosa M. Economic consequences of over-diagnosis of threatened preterm labor. *Int J Gynaecol Obstet.* [in press] (Impact factor: 2.174; Q2)
  16. Suárez-Llanos JP, Benítez-Brito N, **Vallejo-Torres L**, et al. (2017). Clinical and cost-effectiveness analysis of early detection of patients at nutrition risk during their hospital stay through the new screening method CIPA: a study protocol. *BMC Health Service Research* 17(1):292 (Impact factor: 1.606; Q3)
  17. Rodríguez-Caro A, **Vallejo-Torres L**, López-Valcarcel B Unconditional quantile regressions to determine the social gradient of obesity in Spain 1993–2014. *International Journal for Equity in Health.* 2016 (DOI: 10.1186/s12939-016-0454-1) (Impact factor: 2.378; Q2)
  18. **Vallejo-Torres L**, García-Lorenzo B, Castilla-Rodríguez I, Valcárcel-Nazco C, García-Pérez L, Linertová R, Polentinos-Castro E, Serrano-Aguilar P. On the estimation of the cost-effectiveness threshold: why, what, how? *Value in Health.* 2016;19(5):558-66 (Impact factor: 3.279; Q1)
  19. Verhoef TI, Daley R, **Vallejo-Torres L**, Chitty LS, Morris S. Time and travel costs incurred by women attending antenatal tests: A costing study. *Midwifery.* 2016 Sep;40:148-52 (Impact factor: 1.861; Q1)
  20. García-Lorenzo B, **Vallejo-Torres L**, Trujillo-Martín MM, Perestelo-Pérez L, Valcárcel-Nazco C, Serrano Aguilar P. Economic evaluation seeks threshold to support decision-making]. *Rev Esp Salud Publica.* 2015 Dec;89(6):537-44 (Impact factor: 0.78; Q4)
  21. Culme-Seymour EJ, Mason K, **Vallejo-Torres L**, Carvalho C, Partington L, Crowley C, Hamilton NJ, Toll EC, Butler CR, Elliott MJ, Birchall MA, Lowdell MW, Mason C. Cost of Stem Cell-Based Tissue-Engineered Airway Transplants in the United Kingdom: Case Series. *Tissue Eng Part A.* 2016 Feb;22(3-4):208-13 (Impact factor: 3.485; Q2)
  22. **Vallejo-Torres L**, Castilla I, Couce ML, Pérez-Cerdá C, Martín-Hernández E, Pineda M, Campistol J, Arrospide A, Morris S, Serrano-Aguilar P. (2015). Cost-Effectiveness Analysis of a National Newborn Screening Program for Biotinidase Deficiency. *Pediatrics.* 136(2):e424-32 (Impact factor: 5.473; Q1)
  23. Serrano-Aguilar P, Castilla-Rodríguez I, **Vallejo-Torres L**, Valcárcel-Nazco C, García-Pérez L. Neonatal screening in Spain and cost–effectiveness. (2015). *Expert Opinion on Orphan Drugs*, 3(9):971-974 (Impact factor: 0.529; Q4)
  24. Kinge J, **Vallejo-Torres L**, Morris S. (2015). Income-related inequalities in avoidable mortality in Norway: a population-based study using data from 1994-2011. *Health Policy*, 119(7):889-98 (Impact factor: 1.907; Q2)

25. Ramallo-Fariña Y, García-Pérez L, Castilla-Rodríguez I, Perestelo-Pérez L, Wägner AM, de Pablos-Velasco P, Domínguez AC, Cortés MB, **Vallejo-Torres L**, Ramírez ME, Martín PP, García-Puente I, Salinero-Fort MÁ, Serrano-Aguilar PG; INDICA team. (2015). Effectiveness and cost-effectiveness of knowledge transfer and behavior modification interventions in type 2 diabetes mellitus patients-the INDICA study: a cluster randomized controlled trial. *Implementation Science* 9;10(1):47 (Impact factor: 3.47; Q1)
26. **Vallejo-Torres L**, Castilla I, González N, Hunter R, Serrano-Pérez P, Perestelo-Pérez L. (2015). Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model. *Psychological Medicine* 45(7):1459-70 (Impact factor: 5.428; Q1)
27. **Vallejo-Torres L**, Hale D, Morris S, Viner RM. (2014). Income-related inequality in health and health-related behaviour: exploring the equalisation hypothesis. *J Epidemiol Community Health*, Jul;68(7):615-21 (Impact factor: 3.392; Q1)
28. Karlsen S, Morris S, Kinra S, **Vallejo-Torres L**, Viner RM. (2014). Ethnic variations in overweight and obesity among children over time: findings from analyses of the Health Survey for England 1998-2009. *Pediatric Obesity*, 9(3):186-96 (Impact factor: 2.276; Q1)
29. **Vallejo-Torres L**, Morris S, Kinge JM, Poirier V, Verne J. (2014). Measuring current and future cost of skin cancer in England. *Journal of Public Health*, 36(1):140-8 (Impact factor: 1.993; Q2)
30. Orueta JF, García-Álvarez A, Alonso-Morán E, **Vallejo-Torres L**, Nuño-Solinis R. (2013). Socioeconomic variation in the burden of chronic conditions and health care provision - analyzing administrative individual level data from the Basque Country, Spain. *BMC Public Health*, 22;13(1):870 (Impact factor: 2.08; Q2)
31. **Vallejo-Torres L**, Morris S. (2013). Income-related inequity in health care utilisation among individuals with cardiovascular disease in England – accounting for vertical inequity. *Health Economics*, 22(5):533-53 (Impact factor: 2.232; Q1)
32. Christensen M, Morris S, **Vallejo-Torres L**, Vincent C, Mayer SA. (2012). Neurological impairment among survivors of intracerebral hemorrhage: The FAST trial. *Neurocritical Care* 16(2): 224-231 (Impact factor: 3.038)
33. Christensen M, Morris S, Banner C, Lefering R, **Vallejo-Torres L**, Boullion B. (2011). Quality of Life after Severe Trauma: Results of the Global Recombinant Factor VII Trauma Trial. *Journal of Trauma*, 70(6):1524-31 (Impact factor: 2.478; Q1)
34. **Vallejo-Torres L**, Steuten L, Parkinson B, Girling A, Buxton M. (2011). Integrating Health Economics into the product development cycle: the case study of absorbable pins. *Medical Decision Making*, 31(4):596-610 (Impact factor: 2.329; Q1)
35. **Vallejo-Torres L**, Morris S. (2010). The contribution of smoking and obesity to income-related inequalities in health in England. *Social Science and Medicine*, 71(6):1189-1198 (Impact factor: 2.742;Q1)
36. **Vallejo-Torres L**, Morris S. (2010). Factors associated with the use of primary care services: the role of practice nurses. *European Journal of Health Economics*, 12(4):373-81 (Impact factor: 1.755;Q1)
37. Steiner T, Vincent C, Morris S, Davis S, **Vallejo-Torres L**, Christensen MC. (2010). Neurosurgical Outcomes After Intracerebral Hemorrhage: Results of the Factor Seven for Acute Hemorrhagic Stroke Trial (FAST). *Journal of Stroke and Cerebrovascular Diseases*, 20(4):287-94 (Impact factor: 1.680; Q4)

38. **Vallejo-Torres L**, Morris S, Carr-Hill R, Dixon P, Law M, Rice N, Sutton M. (2009). Can regional resource shares be based only on prevalence data? An empirical investigation of the proportionality assumption. *Social Science and Medicine*, 69(11):1634-42 (Impact factor: 2.699; Q1)
39. Steuten L, **Vallejo-Torres L**, Bastide P, Buxton M. (2009). Analysing uncertainty around costs of innovative medical technologies: The case of fibrin sealant (QUIXIL ®) for total knee replacement, *Health Policy*, 89(1):46-57 (Impact factor: 1.348; Q3)
40. **Vallejo-Torres L**, Steuten L, Buxton M, Girling AJ, Lilford RJ, Young T. (2008). Integrating health economics modelling in the product development cycle of medical devices: a Bayesian approach. *International Journal of Technology Assessment in Health Care*, 24(4):459-64 (Impact factor: 1.439; Q3)
41. Steuten L, **Vallejo-Torres L**, Young T, Buxton M. (2008). Transferability of economic evaluations of medical technologies: a new technology for orthopedic surgery. *Expert Review of Medical Devices*, 5(3):329-36 (Impact factor: 2.071; Q2)

## **PARTICIPATION IN FUNDED RESEARCH PROJECTS**

---

1. How much should a health care system pay for health? – aligning population preferences and budget constraints. Ministerio de Ciencia, Innovación y Universidades. Programa Estatal de I+D+i orientada a los retos de la sociedad. Principal investigator: Laura Vallejo-Torres. 2019-2021. Principal Investigator.
2. Public-Private Liaison in Health: quality, sustainability and changes in the Spanish framework. Ministerio de Ciencia, Innovación y Universidades. Programa Estatal de I+D+i orientada a los retos de la sociedad. Principal investigator: Beatriz González López Valcárcel. 2018-2020. Member of the research team.
3. PECUNIA, Programme in Costing, resource use measurement and outcome valuation for Use in multi-sectoral National and International health economic evaluations. European Commission Horizon 2020. Methods research for improved health economic evaluation. Principal investigator: Judith Simon. 2018-2020. Co-applicant/co-investigator.
4. Effectiveness and cost-effectiveness of a multicomponent strategy to implement a clinical practice guideline and improve health outcomes in people with Systemic Erythematosus Lupus. Principal Investigator: María del Mar Trujillo. Funding organisation: Instituto de Salud Carlos III. 2016-2018. Spanish Ministry of Health. Co-applicant.
5. Cost-effectiveness evaluation of CIPA screening tool for patients with nutritional risk at hospital admission. Principal Investigator: Pablo Suárez. Funding organisation: Instituto de Salud Carlos III. 2015-2017. Spanish Ministry of Health. Co-applicant.
6. Social-economic burden and health-related quality of life in patients with Systemic Lupus Erythematosus and their carers in Spain. Principal Investigator: Renata Linertová. 2014-2016. Funding organisation: Instituto de Salud Carlos III. 2014-2016. Spanish Ministry of Health. Co-applicant.
7. Economics of prevention and lifestyles. From evidence to policy. Principal Investigator: Beatriz González López-Valcárcel. Funding organisation: Spanish Ministry of Economics. 2015-2018. Collaborator.

8. Improving Biomedical Research and Innovation in the Canary Island (IMBRAIN). Principal Investigator: Rafael Alonso Solís. Funding organisation: European Commission 7th Framework Programme. 2013-2015. Researcher.
9. Pre-pregnancy health and care. Principal Investigator: J. Stephenson. Funding organisation: Department of Health Policy Review Programme. 2012. Researcher.
10. Improving assessment and management of obesity in UK children and adolescents. Principal Investigator: R. Viner. Funding Organisation: NIHR Programme Grants for Applied Research. 2012. Researcher.
11. Comprehensive staging of newly diagnosed lung and colorectal cancer: Prospective multicentre comparison of whole body Magnetic Resonance Imaging with standard diagnostic imaging pathways. Principal Investigator: S. Taylor. Funding organisation: NIHR Health Technology Assessment. 2011-2013. Researcher
12. Diagnostic accuracy for the extent and activity of newly diagnosed and relapsed Crohn's disease: Multicentre prospective comparison of Magnetic resonance imaging and small bowel ultrasound. Principal Investigator: S. Taylor. Funding organisation: NIHR Health Technology Assessment. 2011-2013. Researcher.
13. Impact of macroeconomic conditions on obesity in children, adolescents and adults. Principal Investigator: T. Stephenson. Funding Organisation: Department of Health Policy Research Programme. 2012-2013. Researcher.
14. Cost-effectiveness of Physiological Science Service Accreditation (PSSA). Principal investigator: S. Morris. Funding organisation: Department of Health. 2011. Co-applicant.
15. Economic analysis of the cost of skin cancer in England, including projections to 2020. Principal Investigator: S. Morris. Funding Organisation: South West Public Health Observatory. 2009. Researcher.
16. Review of the Needs Formulae for Hospital Services and Prescribing Activity in England. Combining Age-Related and Additional Needs (CARAN) report. Principal investigator: S. Morris. Funding organisation: Department of Health. 2008. Co-applicant

## **CONFERENCE PRESENTATIONS**

---

1. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Economists' Study Group meeting, Gran Canaria, Spain, 2016 (Oral presentation)
2. Estimating a cost-effectiveness threshold for the Spanish NHS. Spanish Health Economics Conference, Murcia, Spain, 2016 (Oral presentation)
3. Estimación del umbral de coste-efectividad en España. XXXIV Annual Meeting of the Spanish Society of Epidemiology, Seville, Spain, 2016 (Oral presentation)
4. On the estimation of the cost-effectiveness threshold: why, what, how? Spanish Health Economics Conference, Granada, Spain, 2015 (Oral presentation)
5. The monetary value of a QALY: is the dilemma really over? Health Economists' Study Group meeting, Leeds, UK, 2015 (Oral presentation)
6. The impact of primary care supply on quality of care. American Society of Health Economists Congress (ASHEcon). Los Angeles, USA, 2014 (Oral presentation)
7. Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model.

- Health Technology Assessment International (HTAi), Washington, USA, 2014 (Oral presentation)
8. Cost-effectiveness analysis of newborn screening for biotinidase deficiency. Spanish Health Economics Conference, Pamplona, Spain, 2014 (Oral presentation)
  9. Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model. Spanish Health Economics Conference, Pamplona, Spain, 2014 (Poster presentation)
  10. Income-related inequality in health and health-related behaviour: exploring the equalisation hypothesis. Spanish Health Economics Conference, Santander, Spain, 2013 (Oral presentation)
  11. The impact of primary care supply on quality of care in England. Spanish Health Economics Conference, Bilbao, Spain, 2012 (Oral presentation)
  12. The impact of primary care supply on quality of care in England. Health Economists' Study Group meeting, Oxford, UK, 2012 (Oral presentation)
  13. The impact of macroeconomic conditions on obesity in adults and children in England. Health Economists' Study Group meeting, Marseilles, France, 2012 (Oral presentation)
  14. On the measurement of vertical inequity in health care utilisation – emphasising the need dimension. International Health Economics Association Congress, Toronto, Canada, 2011 (Oral presentation)
  15. Vertical and horizontal inequity in area level allocations of cancer spending in England. Health Economists' Study Group meeting, Bangor University, UK, 2011 (Oral presentation)
  16. Vertical and horizontal inequity in area level allocation of health care resources in cancer programme in England. Spanish Health Economics Conference, Mallorca, Spain, 2011 (Oral presentation)
  17. Measuring vertical equity in health care utilisation using a concentration index approach: a comparison of estimates using socioeconomic ranks and need ranks. European Conference of Health Economics, Helsinki, Finland, 2010 (Oral presentation)
  18. Measuring vertical equity in health care utilisation: a comparison of estimates using socioeconomic ranks and need ranks. Spanish Health Economics Conference, Valencia, Spain, 2010 (Oral presentation)
  19. The contribution of smoking and obesity to income related inequality in health in England. Health Economists' Study Group meeting, The University of Manchester, UK, 2009 (Oral presentation)
  20. Socioeconomic inequity in the delivery of health care in England: accounting for vertical inequity. Health Economists' Study Group meeting, Sheffield University, UK, 2009 (Oral presentation)
  21. The contribution of smoking and obesity to income related inequality in health in England. Spanish Health Economics Conference, Malaga, Spain, 2009 (Oral presentation)
  22. Integrating health economics modelling in the product development cycle of medical devices: a Bayesian approach. Annual Health Technology Assessment international meeting, Montreal, Canada, 2008 (Oral presentation)

23. Enlightened development and informed decision making for medical devices to improve user access. Workshop at the annual Health Technology Assessment international meeting, Montreal, Canada, 2008 (Oral presentation)
24. An investigation of the proportionality assumption underpinning the epidemiological approach to resources allocation. Health Economists' Study Group meeting, East Anglia University, UK, 2008 (Oral presentation)
25. The determinants of the use of practice nurse services in England. Spanish Health Economics Conference, Salamanca, Spain, 2008 (Oral presentation)
26. The determinants of the use of practice nurse services in England. Health Economists' Study Group meeting, Brunel University, UK, 2007 (Oral presentation)
27. Demand for Insecticide-Treated Nets (ITNs) in Surat, India: Moving from Willingness to Pay for One to Many ITNs. International Health Economics Association Congress, Copenhagen, Denmark, 2007 (Oral presentation)
28. Demand for Insecticide-Treated Nets (ITNs) in Surat, India: Moving from Willingness to Pay for One to Many ITNs. Health Economists' Study Group meeting, Brunel University, UK, 2007 (Oral presentation)

## **INVITED SEMINARS**

---

1. "Socio-economic evaluation in health research", Universidad Internacional Menéndez Pelayo Summer School, June 2016, Santander, Spain.
2. On the estimation of the cost-effectiveness threshold: why, what, how? Universidad Internacional Menéndez Pelayo Summer School, July 2015, Santander, Spain.
3. The impact of innovation on the sustainability of the health care system. National Congress of the Spanish Society of Pharmacists in Primary Care, October 2014, Mérida, Spain (Inaugural conference).
4. On the estimation of the monetary value of a Quality-Adjusted Life Year (QALY). Research Centre in Economics and Health (CRES), Universitat Pompeu Fabra, October 2014, Barcelona, Spain.
5. Equity in health and health care. Basque Institute of Medical Innovation, December 2012, Bilbao, Spain.
6. Health, equity and quality of health services: an econometric approach. Universidad de Las Palmas de Gran Canaria, December 2012, Las Palmas de Gran Canaria, Spain.
7. On the measurement of vertical inequity in health care utilisation – emphasising the need dimension. Erasmus University, January 2012, Rotterdam, the Netherlands.
8. The cost of skin cancer in England. The Economics of cancer workshop. National Cancer Intelligence Network, October 2011, London, UK.
9. An economic analysis of vertical equity in the delivery of health care in England. Health Economics Research Group, Brunel University, January 2011, London UK.
10. An economic analysis of vertical equity in the delivery of health care in England. Health, Econometrics and Data Group, University of York, December 2010, York, UK.
11. Testing the proportionality assumption that underpins the epidemiological approach; Department of Health, April 2008, London, UK.



## **HONOURS, GRANTS, FELLOWSHIPS AND AWARDS**

---

Award for best paper presented by a young researcher at the 36<sup>th</sup> Spanish Health Economics Conference (AES), Murcia, 2016.

Capacity Building Studentship in Health Economics. 2008-2011. Granted by the Medical Research Council, UK

Financial support to attend the iHEA World Congress, Toronto, 2011. Granted by the Spanish Health Economics Association.

Financial support to attend the Spanish Health Economics Conference (AES), Malaga, 2009. Granted by the Spanish Health Economics Association.

Financial support to attend the European Conference of Health Economics (ECHE). Helsinki, 2010. Granted by the Spanish Health Economics Association

Undergraduate Fellowship. Granted by the Spanish Ministry of Education and Science, for the period 2003-2004

Undergraduate Fellowship. Granted by the Department of Applied Economic Analysis, Universidad de Las Palmas de Gran Canaria, for the period 2002-2003

## **OTHER PROFESSIONAL ACTIVITIES**

---

Referee: Social Science and Medicine; Value in Health; Gaceta Sanitaria; Health Policy; Health Economics; Journal of Health Economics; British Medical Bulletin; Applied Economic Perspectives and Policy; Nicotine & Tobacco Research

Professional Memberships: Spanish Health Economics Association; Health Economists' Study Group; International Health Economics Association

President of the Board of Directors of the Spanish Association of Health Economics